Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.

Oncotarget · 2015 · PMC4467394 · PMID 25691057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

We showed that lapatinib treatment in 100 nM and 250 nM for 8 hours induced an increasing trend of NRG1 mRNA expression in SK-BR-3 cells (Fig. 1C ), although the increase was not statistically significant.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.